Literature DB >> 28984748

Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring.

Michał Wiciński1, Mateusz M Węclewicz.   

Abstract

PURPOSE OF REVIEW: Clozapine-induced agranulocytosis/granulocytopenia (CIAG) is an uncommon condition, but potentially fatal in consequences. The pathogenesis, despite multiple experiments, is not fully elucidated. The current theory suggests reactive oxygen species - nitrenium ion as the most important factor of CIAG. In this review, mechanism and monitoring of CIAG will be discussed. RECENT
FINDINGS: The mechanism of CIAG seems to have an autoimmune background, rather than toxic. Clozapine has a high potential to undergo biochemical activation to nitrenium ion. The role of the primary metabolite of clozapine - N-desmethylclozapine - is in decline. Nitrenium ion is mainly synthesized by CYP3A4, CYP2D6, and myeloperoxidase system in leukocytes. An important component of CIAG pathogenesis is genetic aberration in human leukocyte antigen genes, and also genes associated with apoptosis and ubiquitination. Clozapine monitoring regimes differ between countries. US-derived clozapine Risk Evaluation and Mitigation Strategy is the most tolerant in the aspect of blood parameter thresholds. Therefore, it provides the opportunities for physician to continue the treatment and also to rechallenge the drug after the episode of CIAG.
SUMMARY: Each patient with the episode of CIAG should be assessed individually, with special attention to risk factors and drug-drug interactions. Upon that, the decision about clozapine rechallenge or withdrawal should be made.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28984748     DOI: 10.1097/MOH.0000000000000391

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  21 in total

Review 1.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

2.  Re-titration rates after clozapine-induced neutropenia or agranulocytosis: A case report and literature review.

Authors:  Mina Boazak; Benjamin Kahn; Lindsay Cox; James Ragazino; David R Goldsmith; Robert O Cotes
Journal:  Clin Schizophr Relat Psychoses       Date:  2018-06-26

Review 3.  A Look at Genetic Linkage between Clozapine-induced Agranulocytosis, Malignant Hyperthermia, Neuroleptic Malignant Syndrome, and Statin-induced Myopathy.

Authors:  Nitin Pothen; Shveta Kansal; Theodor Rais; Stacy Doumas; Ramon Solhkhah
Journal:  Innov Clin Neurosci       Date:  2019-11-01

4.  Monocytopenia in clozapine-induced agranulocytosis: insights into pathophysiology and treatment.

Authors:  Rajvi Patel; Ateaya Lima; Christopher Burke; Mark Hoffman
Journal:  BMJ Case Rep       Date:  2019-01-18

5.  Treatment Capacity and Clinical Outcomes for Patients With Schizophrenia Who Were Treated With Electroconvulsive Therapy: A Retrospective Cohort Study.

Authors:  Joanne E Plahouras; Gerasimos Konstantinou; Tyler S Kaster; Daniel Z Buchman; George Foussias; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

Review 6.  Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.

Authors:  Giovanni Ostuzzi; Davide Papola; Chiara Gastaldon; Georgios Schoretsanitis; Federico Bertolini; Francesco Amaddeo; Alessandro Cuomo; Robin Emsley; Andrea Fagiolini; Giuseppe Imperadore; Taishiro Kishimoto; Giulia Michencigh; Michela Nosé; Marianna Purgato; Serdar Dursun; Brendon Stubbs; David Taylor; Graham Thornicroft; Philip B Ward; Christoph Hiemke; Christoph U Correll; Corrado Barbui
Journal:  BMC Med       Date:  2020-07-15       Impact factor: 8.775

7.  Risk Factors for Relapse of Childhood B Cell Acute Lymphoblastic Leukemia.

Authors:  Rongrong Zhang; Haiyan Zhu; Yufang Yuan; Jiou Zhao; Xiaochun Yang; Zhaofang Tian
Journal:  Med Sci Monit       Date:  2020-07-03

Review 8.  Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis.

Authors:  Shusuke Numata; Hidehiro Umehara; Tetsuro Ohmori; Ryota Hashimoto
Journal:  Front Pharmacol       Date:  2018-09-26       Impact factor: 5.810

Review 9.  A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.

Authors:  Jose de Leon; Can-Jun Ruan; Georgios Schoretsanitis; Carlos De Las Cuevas
Journal:  Psychother Psychosom       Date:  2020-04-14       Impact factor: 17.659

Review 10.  Neuroprotective Activity of Sitagliptin via Reduction of Neuroinflammation beyond the Incretin Effect: Focus on Alzheimer's Disease.

Authors:  Michał Wiciński; Eryk Wódkiewicz; Maciej Słupski; Maciej Walczak; Maciej Socha; Bartosz Malinowski; Katarzyna Pawlak-Osińska
Journal:  Biomed Res Int       Date:  2018-08-16       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.